MARKET

KMPH

KMPH

KemPharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3611
-0.0189
-4.97%
After Hours: 0.3900 +0.0289 +8.00% 19:25 01/24 EST
OPEN
0.3900
PREV CLOSE
0.3800
HIGH
0.4000
LOW
0.3611
VOLUME
1.12M
TURNOVER
--
52 WEEK HIGH
2.820
52 WEEK LOW
0.2650
MARKET CAP
14.20M
P/E (TTM)
-0.4046
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of KMPH and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

KMPH News

  • Nasdaq Grants KemPharm’s Request for Extension to Comply with the Market Value of Listed Securities Continued Listing Requirement
  • GlobeNewswire.01/15 13:30
  • Virgin Trains financing among biggest Orlando economic development deals of the year
  • American City Business Journals.12/27/2019 19:41
  • UPDATED: C. Fla. pharmaceutical firm enters debt restructure agreement
  • American City Business Journals.12/26/2019 16:39
  • The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares
  • Benzinga.12/26/2019 12:55

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About KMPH

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company's products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.
More

Webull offers KemPharm Inc (KMPH) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.